Company
United StatesPublic company, NASDAQ: ALNYAlnylam Pharmaceuticals Inc. (NASDAQ: ALNY), Cambridge, MA – FDA Inspections
Inspection records and compliance data for Alnylam Pharmaceuticals Inc. in Cambridge, Massachusetts. 3 FDA inspections on record, 2 Form 483s, last inspected February 25, 2025. Publicly traded as NASDAQ: ALNY.
Company Profile
This profile covers Alnylam Pharmaceuticals Inc. based in Cambridge, Massachusetts, United States.
FDA Inspection History
- FDA inspections
- 3
- OAI
- 0
- VAI
- 2
- NAI
- 1
- Form 483s
- 2
- Warning letters
- 0
First inspected May 4, 2018. Last inspected February 25, 2025.
Most cited issue areas
- Component written specification1 inspection
- Control procedures to monitor and validate performance1 inspection
- Establish reliability of supplier's C of A1 inspection
FDA inspections (3)
| Date | Result | FDA center(s) | Insp. # |
|---|---|---|---|
| February 25, 2025 | VAI | Human Drugs · Drug Quality Assurance | 1262276 |
| September 13, 2019 | NAI | Human Drugs · Drug Quality Assurance | 1109687 |
| May 4, 2018 | VAI | Human Drugs · New Drug Evaluation | 1050730 |
FDA documents
Form 483s (1)
People (2)
Related Companies (10)
Companies with similar regulatory profiles, compliance history, and operations.
Company Information
Name
Alnylam Pharmaceuticals Inc.
Stock ticker
ALNY
Exchange
NASDAQ
Share price
$156.65
Market cap
$21.0B
Price as of
November 13, 2026
FEI Number
3013754451
Address
665 Concord Ave, Cambridge, Massachusetts 02138, United States
Country
United States
ID: 285be436-d642-438b-ac4c-530088c678b8